SAN DIEGO--(BUSINESS WIRE)--Onchilles Pharma, a private biotech company developing pan-cancer therapeutics that leverage the ELANE pathway, a novel innate immune mechanism of action for potent and ...

Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3 rd-generation EGFR inhibitors and outperforms other investigational 4 th-generation inhibitors ...

Atea Pharmaceuticals (AVIR) announced the presentation of new modeling data predicting that the Company’s combination regimen of bemnifosbuvir, ...

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable ...